Floatz logo

Muromonab-Cd3

Leukemia, Myeloid, Chronic(CML)

St. Jude Children's Research Hospitalmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

86 Active assets in the Leukemia, Myeloid, Chronic(CML) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
METHOTREXATE
M.D. Anderson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Muromonab-Cd3 is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
Myelodysplastic Syndrome (MDS)Dormant
BB
Indicative ·
69 / 100
View asset →
paroxysmal nocturnal hemoglobinuriaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →